• Investment Books

  
  

• Smart Investment

  

Aurobindo Pharma is pleased to announce that it has received the final approval for Risperidone oral solution 1mg/ml from the US Food and Drug Administration (USFDA).

Risperidone oral solution 1mg / ml is generic equivalent to Risperdal oral solution 1mg/ml of Ortho-McNeil Janssen.

Risperidone oral solution is indicated in the treatment schizophrenia and falls under the neurological (CNS) segment. This product has a market of approximately USD 68 million for the twelve months ending March 2009 according to Newport. The product will be launched shortly.

Aurobindo now has a total of 102 ANDA approvals (74 final approvals and 28 tentative approvals) from USFDA.

Tags:according to Newport, ANDA approvals, Aurobindo Pharma, falls under the neurological, generic equivalent, launched shortly, market of approximately, Risperidone oral solution, treatment schizophrenia, US Food and Drug Administration (USFDA)

Related Post :

• Unichem gets USFDA nod for API facility at Pithampur
• Aurobindo gets USFDA nod for Cefotaxime injection
• Aurobindo Pharma gets USFDA approval
• Aurobindo Pharma | Aurobindo Pharma Q2FY10 Results | Aurobindo Pharma Results | Aurobindo Pharma Q2 Results | Aurobindo Pharma Q2 Results 2009 | Aurobindo Pharma Latest Quarter Results | Aurobindo Pharma Second Quarter Results | Aurobindo Pharma Q2 cons net profit at Rs 103.1 Crore
• Zydus Pharma gets USFDA nod for Ramipril tablets
• Pfizer to launch 2-3 generic drugs in India by Dec
• Aurobindo gets USFDA nod for Sumatriptan Succinate tablets
• Aurobindo Pharma gets USFDA nod for Zidovudine tablets

• Search

• Investment Books

  
  

• Smart Investment